Nootropic & CNS Research Peptides: A Comprehensive Pillar Guide

What unifies the nootropic peptides as a research category is not a shared receptor, a shared signaling pathway, or even a shared structural family — it is the convergent intent to engage central nervous system targets through short-peptide ligands that recruit fundamentally different molecular machinery. The compounds grouped under this label activate receptor systems as varied as BDNF/TrkB and HGF/c-Met, modulate the melanocortin and tuftsin/GABAergic axes, inhibit TREK-1 potassium channels, engage candidate FPRL-1 and IL6ST receptors on the mitochondrial-derived peptide axis, and — in the Khavinson short-peptide tradition — interact with chromatin and gene expression directly. The category is best read as a mechanism mosaic, not a drug class.

This guide provides a mechanism-organized reference to the eight nootropic peptides currently in the Apex Laboratory catalog — Selank, Semax, Cerebrolysin, Dihexa, DSIP, Humanin, PE-22-28, and Pinealon — covering each compound’s receptor or pathway family, the foundational primary literature anchoring each lineage, the cross-cutting question of how short peptides reach the CNS at all, and the per-compound regulatory framing that distinguishes an internationally approved pharmaceutical (Cerebrolysin) from compounds approved only in the Russian Federation (Selank, Semax) and the five compounds that remain research-only globally.

What “Nootropic Peptides” Names in the Research-Compound Landscape

The phrase nootropic peptides is a research-category convention rather than a pharmacological class. Where small-molecule nootropics — the racetam family, the cholinergic agents, the wakefulness-promoting modafinil chemotype — share at least loose pharmacophore similarities, the peptide compounds collected under this label share only their CNS-targeting research applications and a structural lower bound (typically 3–24 amino acids). Asua and colleagues, in Neuroscience, Asua et al. (2018), reviewed peptide cognitive enhancers under exactly this mechanism-organized framing — establishing synaptic function as a tractable target across structurally unrelated compounds — and the same organizational logic applies to Apex’s eight-compound catalog. Researchers approaching this category are therefore better served by a receptor map than by a list ranked on indication or popularity.

The eight compounds at a glance

Apex’s nootropic and CNS research peptide catalog comprises eight compounds, each tagged here with the single mechanism most directly characterized in its primary literature:

• Selank — heptapeptide tuftsin analog; GABAergic allosteric modulation
• Semax — heptapeptide ACTH(4-10) analog; BDNF/TrkB modulation
• Cerebrolysin 60mg — porcine-brain peptide-and-amino-acid mixture; multi-factor neurotrophic mimicry
• Dihexa 10mg (60pcs) — angiotensin-IV-derived peptidomimetic; HGF/c-Met agonism
• DSIP — nine-amino-acid neuropeptide; sleep-architecture and pleiotropic activity
• Humanin 10mg — 24-amino-acid mitochondrial-encoded peptide; candidate FPRL-1/IL6ST signaling
• PE-22-28 5mg — seven-amino-acid spadin analog; TREK-1 inhibition
• Pinealon 10mg — Glu-Asp-Arg tripeptide; Khavinson bioregulator

The full Apex Research Library indexes these alongside lateral pillars covering tissue repair, longevity, and specialty research peptides.

The seven mechanism families

The mechanism-family taxonomy that organizes the rest of this guide partitions the eight compounds across seven distinct receptor or pathway lineages:

• Neurotrophic-Factor-Mimicking Compounds — Cerebrolysin (NGF/BDNF/GDNF/CNTF-like activity); Dihexa (HGF/c-Met agonism)
• Melanocortin- and BDNF-Pathway Modulators — Semax
• Tuftsin-Derived & GABAergic Anxiolytic Peptides — Selank
• Sleep-Related Neuropeptides — DSIP
• Ion-Channel-Targeted Neurogenesis Compounds — PE-22-28 (TREK-1 inhibition)
• Mitochondrial-Derived CNS-Protective Peptides — Humanin
• Khavinson Bioregulatory Short Peptides (CNS) — Pinealon

The order of these families is not arbitrary: the neurotrophic-factor-mimicking compounds are the most catalog-anchored and have the deepest published clinical literature; the Khavinson bioregulators sit at the opposite end of the evidence-maturity spectrum, shading into the broader Russian short-peptide bioregulator program also covered in the longevity and bioregulator research peptides pillar. Reading the families in sequence walks the researcher from the most-characterized CNS targets toward the most-investigational. The eight compounds also share a brief conceptual relationship with the BPC-157 CNS-protective subset surveyed in the tissue repair research peptides pillar, though that compound is not part of this category.

How Peptide Drugs Reach the CNS — Blood-Brain Barrier Transport

Before engaging any of the seven mechanism families, every CNS research peptide must first cross the blood-brain barrier (BBB) — and the eight catalog compounds use at least four distinct transport strategies to do so. The most comprehensive modern reference on the topic is Banks (2015) in Peptides, which surveys the saturable, receptor-mediated, and adsorptive transcytosis mechanisms that allow short peptides to engage CNS receptors at all and identifies these mechanisms as the basis for CNS-directed drug design. The foundational characterization of these transport systems is older still: Banks and Kastin (1987), in Life Sciences, established specificity, stereo-specificity, saturability, and noncompetitive inhibition as documented properties of peptide BBB transport — observations that anchor four decades of subsequent CNS-peptide pharmacokinetic research.

Saturable transport, intranasal delivery, and designed BBB-penetrant analogs

The eight catalog compounds illustrate the diversity of transport strategies in use. Selank and Semax are administered intranasally in essentially all of the published Russian Academy of Sciences mechanism research, partially bypassing systemic circulation — an approach detailed in the paired-compound Selank and Semax research guide. Cerebrolysin is given parenterally (intravenous or intramuscular) in its published clinical record and shows central biological effects despite a short plasma half-life of its individual peptide constituents — a pharmacokinetic profile examined in detail in the Cerebrolysin research guide. Dihexa was deliberately engineered to be metabolically stable, orally active, and BBB-penetrant — properties absent in its angiotensin-IV parent. Humanin is endogenously produced within mammalian cells and therefore reaches CNS tissue from internal pools rather than from peripheral administration alone. The Khavinson tripeptide Pinealon and the spadin-derived heptapeptide PE-22-28 are short enough that simple permeation contributes alongside any saturable carriers.

Neurotrophic-Factor-Mimicking Compounds

Cerebrolysin and Dihexa share an unlikely commonality despite their structural distance: both are characterized in the published literature as recapitulating endogenous neurotrophic-factor activity (NGF, BDNF, GDNF, CNTF, HGF) without sharing those factors’ molecular identity. Cerebrolysin is a porcine-brain peptide-and-amino-acid hydrolysate with broad neurotrophic-factor-like pharmacodynamics; Dihexa is an angiotensin-IV-derived small-molecule peptidomimetic that engages the HGF/c-Met receptor system. Their convergence on neurotrophic-factor-like pharmacodynamics — across radically different molecular scaffolds — is the connective tissue of this family, and the deepest-evidence anchor of the catalog.

Cerebrolysin

Cerebrolysin is composed, by total nitrogen content, of approximately 25% low-molecular-weight peptides (under 10 kDa) and 75% free amino acids — a composition characterized in Hartbauer et al. (2001) in the Journal of Neural Transmission, which documented antiapoptotic activity localized to the peptide fraction in chick cortical neuron cultures. Subsequent mechanism work has characterized multiple discrete pathway engagements: Stroke, Zhang et al. (2013) demonstrated that the Sonic hedgehog pathway mediates Cerebrolysin-enhanced neurogenesis and white-matter remodeling in a rat embolic-stroke model — a finding established by cyclopamine pharmacological blockade. The proNGF/NGF balance is a separate documented axis, examined by Ubhi et al. (2013) in hAPP transgenic mice, where the mixture was reported to shift the ratio toward mature NGF and protect cholinergic neurons. Clinical evidence is the deepest in this category. The multicenter Stroke, Muresanu et al. (2016) CARS RCT reported a beneficial effect on functional and global outcome in early stroke rehabilitation. The larger Stroke, Heiss et al. (2012) CASTA trial (n≈1,070) returned a neutral confirmatory primary endpoint with a favorable trend in the severely-affected subgroup. The 2023 Cochrane review, Cochrane Database of Systematic Reviews, Ziganshina et al. (2023), concluded with moderate-certainty evidence that Cerebrolysin probably has no beneficial effect on preventing all-cause death in acute ischaemic stroke. The same review noted a potential increase in non-fatal serious adverse events — a finding that anchors honest evidence-base description for this compound. Cerebrolysin is approved as a pharmaceutical primarily in Austria and parts of Eastern Europe, plus several Asian markets; the research-grade Cerebrolysin compound guide material sold by Apex is not interchangeable with the approved pharmaceutical product and is intended for in-vitro laboratory research use only.

Dihexa

Dihexa (N-hexanoic-tyrosine-isoleucine-(6) aminohexanoic amide; CAS 1401708-83-5; MW 507.63 g/mol) is a small-molecule peptidomimetic developed at Washington State University as part of an angiotensin-IV-analog research program. The canonical contemporary review is Progress in Neurobiology, Wright et al. (2015), which characterized Dihexa as metabolically stable, BBB-penetrant, and orally active — three properties absent in the parent peptide — and reported that the molecule augments synaptic connectivity through HGF/c-Met-dependent formation of new functional synapses. Independent replication outside the Harding/Wright group is documented by Brain Sciences, Sun et al. (2021), which reproduced cognitive rescue in the APP/PS1 transgenic Alzheimer’s mouse model and identified the brain AngIV/PI3K/AKT axis as a tractable mechanistic target. A dedicated Dihexa research guide is forthcoming and will examine the structural-pharmacokinetic relationship in greater depth.

Melanocortin- and BDNF-Pathway Modulators

Both Semax and Selank emerged from the Russian Academy of Sciences Institute of Molecular Genetics through a shared Pro-Gly-Pro stabilization strategy applied to fundamentally different parent fragments — and in Semax’s case, the parent is the adrenocorticotropic hormone (4-10) fragment, with the published mechanism work centered on the melanocortin axis and the BDNF/TrkB neurotrophin signaling pathway. Semax is the sole Apex catalog compound in this family.

Semax

Semax (Met-Glu-His-Phe-Pro-Gly-Pro; CAS 80714-61-0; MW 813.93 g/mol) is a heptapeptide derived from ACTH(4-10) by appending the C-terminal Pro-Gly-Pro tripeptide to extend metabolic stability without the corticotropic activity of the parent fragment. The BDNF/TrkB mechanism was characterized in two complementary 2006 papers from the Dolotov laboratory: Brain Research, Dolotov et al. (2006) reported that Semax modulates expression and activation of the hippocampal BDNF/TrkB system in rat, and the companion paper in Journal of Neurochemistry, Dolotov et al. (2006) demonstrated saturable specific binding sites for Semax in rat basal forebrain alongside increased BDNF protein levels — a binding profile that distinguishes Semax from generic plasma-protein interaction. Melanocortin-receptor pharmacology (competitive antagonism at MC4 and MC5 has been described in adjacent literature) sits alongside this BDNF signal as a documented but separately characterized axis; researchers investigating the melanocortin-pathway aspects can also consult the specialty research peptides pillar for crossover with melanocortin agonist compounds outside the cognitive-research category. Clinical evidence comes from a Russian non-randomized observational study of 110 ischemic-stroke patients reported in Gusev et al. (2018), which documented increased plasma BDNF and improved Barthel-index scores under intranasal Semax 6,000 mcg/day in two ten-day courses; the design was non-randomized and the geographic isolation of the Russian clinical literature is a material limitation in evidence interpretation. Semax is approved as a medication in the Russian Federation; in all other jurisdictions it is classified as a research chemical. Detailed compound-level coverage continues in the existing Russian Academy of Sciences peptide program guide.

Tuftsin-Derived & GABAergic Anxiolytic Peptides

Selank’s anxiolytic mechanism enters this category through tuftsin — the immunomodulatory tetrapeptide Thr-Lys-Pro-Arg — extended at the C-terminus with the same Pro-Gly-Pro stabilization motif used in Semax. The published mechanism work characterizes Selank as a GABAergic-pathway modulator distinct from benzodiazepine pharmacology. Selank is the sole Apex catalog compound in this family and shares Russian Academy of Sciences institutional provenance with Family 2 — a structural symmetry the literature itself exploits.

Selank

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; CAS 129954-34-3; MW 751.87 g/mol) is a heptapeptide tuftsin analog developed at the Russian Academy of Sciences Institute of Molecular Genetics through the same Pro-Gly-Pro stabilization strategy applied to Semax. The GABAergic mechanism is characterized in Vyunova et al. (2018) in Protein and Peptide Letters, which hypothesized and demonstrated that Selank’s anxiolytic-pathway activity is associated with subtype-selective concentration-dependent allosteric modulation of GABA receptors. Gene-expression evidence reinforces the framing: Frontiers in Pharmacology, Volkova et al. (2016) reported that Selank affects expression of GABAergic-system genes in rat frontal cortex. The same paper characterized the compound’s effects as “complex effects on nerve cells, [with] one of its possible molecular mechanisms… associated with allosteric modulation of the GABAergic system.” A companion in-vitro study in the IMR-32 neuroblastoma line, Filatova et al. (2017), reported no direct effect on GABAergic-system mRNA in that specific cell line. The Filatova paper still supported the broader hypothesis that the peptide may affect GABA–GABAA receptor interaction — an evidence-base nuance that researchers should preserve when characterizing the mechanism. Russian clinical literature on Selank includes a comparative Generalized Anxiety Disorder trial against medazepam reported in Zozulia et al. (2008), which described comparable anxiolytic effects to the benzodiazepine comparator alongside antiasthenic and psychostimulant components. The clinical literature on Selank is geographically isolated to Russian Federation centers; researchers reading this evidence should weight that constraint accordingly. Selank is an approved medication in the Russian Federation and is classified as a research chemical in all other jurisdictions. The paired-compound history is examined further in the Selank and Semax research guide.

Sleep-Related Neuropeptides

Unlike most CNS-active peptides, DSIP’s canonical receptor remains unidentified after five decades of research — and that epistemic gap defines the family. Sleep-architecture and circadian-rhythm investigation supply the canonical research applications here, but relative to the BDNF, GABAergic, and HGF/c-Met families above, the receptor pharmacology is markedly less resolved. Researchers reading this literature must hold that fact actively in view.

DSIP

DSIP — Delta Sleep-Inducing Peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; CAS 62568-57-4; MW 848.82 g/mol) — was characterized by the Schoenenberger and Monnier laboratories at the University of Basel in the 1970s, with the foundational synthesis-and-activity paper appearing as Pflügers Archiv, Schoenenberger et al. (1978). That paper documented an approximately 35% mean increase in delta-EEG activity in neocortex and limbic cortex following synthetic DSIP administration and proposed a neurohumoral modulating-and-programming activity. The peptide was originally isolated from rabbit cerebral venous blood collected during low-frequency electrical stimulation of intralaminar thalamic nuclei — an animal-source disclosure that the Apex Editorial Team includes as factual context. Activity beyond sleep architecture was reviewed comprehensively in Graf and Kastin (1984) in Neuroscience and Biobehavioral Reviews, which catalogued effects across electrophysiological activity, neurotransmitter levels, circadian and locomotor patterns, hormonal levels, and behavioral assays in multiple mammalian species. The canonical DSIP receptor has not been definitively identified in the published literature — a persistent gap that any DSIP mechanism description must hedge accordingly. Clinical research on DSIP is limited; the most-cited primary source remains Schneider-Helmert (1987), a 14-subject placebo-controlled trial in chronic insomnia. The trial size is small and the publication is older; researchers should treat this evidence as a foundation for hypothesis generation rather than as evidence of established clinical practice. A dedicated DSIP research guide is forthcoming.

Ion-Channel-Targeted Neurogenesis Compounds

Among the eight compounds covered here, PE-22-28’s published research base is the narrowest — essentially confined to the Mazella/Borsotto laboratory at the CNRS Institut de Pharmacologie Moléculaire et Cellulaire. The primary documented mechanism targets a specific ion channel: the TREK-1 two-pore-domain potassium channel of the K2P family. PE-22-28 is the Apex catalog representative of this lineage, and its evidence base is the thinnest among the eight compounds in this guide.

PE-22-28

PE-22-28 is a seven-amino-acid analog of spadin (PE-12-28) — itself a peptide cleaved from the propeptide of sortilin and characterized as a TREK-1 inhibitor by the Mazella and Borsotto group at the CNRS Institut de Pharmacologie Moléculaire et Cellulaire. The parent-compound mechanism work is documented in PLoS Biology, Mazella et al. (2010), which positioned spadin as a candidate fast-onset antidepressant of new generation acting through TREK-1 inhibition. The PE-22-28-specific characterization appears in Frontiers in Pharmacology, Djillani et al. (2017), which reported a TREK-1 IC50 in the picomolar range (approximately 0.12 nM versus 40–60 nM for spadin), in-vivo stability extended to roughly 23 hours (versus approximately 7 hours for spadin), antidepressant-pathway activity in the mouse forced-swim test, and induced hippocampal neurogenesis in a four-day treatment paradigm. The published primary literature on PE-22-28 is very limited. The compound’s research record consists primarily of work from a single laboratory — the Mazella and Borsotto group at CNRS — and lacks independent replication outside that program at the time of writing. Researchers integrating PE-22-28 into experimental design should treat the literature as a foundation for hypothesis generation rather than as a settled mechanism, and should weight the absence of cross-laboratory replication in evidence interpretation. PE-22-28 is not approved by the FDA, EMA, or any regulatory agency for human therapeutic use; the research-grade material is sold for in-vitro laboratory research only. A dedicated PE-22-28 research guide is forthcoming.

Mitochondrial-Derived CNS-Protective Peptides

Humanin is unique among the compounds covered here in being encoded by mitochondrial DNA rather than the nuclear genome — a discovery that, when first reported in 2001, expanded the conceptual map of mitochondria from energy-producing organelles to active signaling participants. The published literature characterizes Humanin and its sibling mitochondrial-derived peptides (MDPs) as cytoprotective signaling factors. Humanin is the founding member and the Apex catalog representative of this family; the broader MDP literature also overlaps with the longevity-research-peptide cluster.

Humanin

Humanin is an approximately 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA; MW 2687.1 g/mol) encoded within the mitochondrial 16S rRNA gene. The discovery paper, Proceedings of the National Academy of Sciences, Hashimoto et al. (2001), identified the peptide by functional cloning from a brain cDNA library and demonstrated rescue of neuronal cell death from familial Alzheimer’s disease genes and amyloid-beta. Endogenous in-vivo production was documented in Tajima et al. (2002), which distinguishes Humanin from compounds whose biological presence is exclusively a function of synthetic administration. Downstream signaling has been characterized in Journal of Biological Chemistry, Takeshita et al. (2013), which identified SH3BP5 as a downstream effector that binds and directly inhibits c-Jun N-terminal kinase (JNK) through MAPK-interaction motifs, providing antiapoptotic activity against Alzheimer-related neuronal death. The receptor landscape for Humanin remains less settled than the downstream signaling: candidate receptors documented in the published literature include FPRL-1/FPRL-2 (formyl-peptide receptor-like 1 and 2) and an IL6ST/CNTFR/WSX-1 trimeric receptor complex. Researchers should describe the receptor identification as a set of proposed targets rather than as a single canonical receptor. The legitimate cross-cluster relationship to the mitochondrial-derived-peptide literature — alongside MOTS-c, SHLP family members, and SS-31 — places Humanin at the intersection of CNS research and the broader longevity and bioregulator pillar. A dedicated Humanin and MOTS-c research guide is forthcoming.

Khavinson Bioregulatory Short Peptides (CNS)

Pinealon belongs to a class of short peptides developed by the Khavinson group on the bioregulator concept — that endogenous tetra-, tri-, and dipeptides act as tissue- or organ-system-specific gene-expression modulators. The program was founded at the Saint Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues, and has generated dozens of these short peptides over four decades. Pinealon is the CNS-focused member of the family; the same lineage produced Epithalon — covered in the existing Epithalon research guide — and the broader bioregulator corpus that backbones the Apex longevity cluster.

Pinealon

Pinealon (Glu-Asp-Arg / EDR; MW approximately 358 g/mol) is a tripeptide whose CNS mechanism work is anchored in Rejuvenation Research, Khavinson et al. (2011). That paper reported that restriction of reactive oxygen species accumulation and cell mortality is saturated at lower concentrations while cell-cycle modulation continues at higher concentrations — a two-mechanism framing in which Pinealon shows antioxidant activity at one concentration range and direct interaction with the cell genome at another. The bioregulator concept itself — short peptides that interact with chromatin, DNA, and nucleosomes to regulate gene expression — was reviewed by Anisimov and Khavinson (2010) in Biogerontology, which collected long-term-treatment evidence across the broader Khavinson short-peptide corpus including life-span and biomarker observations in rodent models. In-vivo neuroprotection in a rat prenatal hyperhomocysteinemia model was characterized by Arutjunyan et al. (2012), which documented improved spatial-orientation and learning performance in offspring receiving Pinealon and noted that the protective effect operates without lowering homocysteine itself — distinguishing the mechanism from metabolic correction. The Saint Petersburg Institute attribution is the canonical institutional context; researchers approaching the Khavinson literature should treat it as a distinct national research program with its own historical conventions rather than as an extension of Western neuroscience traditions. Pinealon is not approved by the FDA, EMA, or any regulatory agency for human therapeutic use. The cross-cluster context with the Apex longevity catalog is detailed in the longevity research peptides pillar, and a dedicated Pinealon and PE-22-28 research guide is forthcoming.

Reading the Evidence Across the Category

The seven mechanism families above span an unusually wide range of evidence-maturity levels — wider than is typical within a single research-peptide category. A pillar guide that reports each compound at the same confidence level would be wrong about most of them. The evidence stratification is itself a finding researchers should carry into experimental design.

Evidence-maturity stratification

At one end of the spectrum, Cerebrolysin’s research record includes multiple multicenter randomized controlled trials (CARS, CASTA), a 2023 Cochrane systematic review with moderate-certainty conclusions, and decades of preclinical mechanism work — and is summarized in Brainin (2018) in Expert Review of Neurotherapeutics. Synergy work with cholinesterase inhibitors in ApoE4-stratified Alzheimer’s patients is documented in International Journal of Neuropsychopharmacology, Alvarez et al. (2016). Selank, Semax, and Humanin sit at intermediate evidence-maturity — substantive primary mechanism literature plus, for the Russian compounds, geographically isolated Russian-language clinical trial publications. DSIP and Pinealon occupy an older-but-thinner band — foundational characterization decades old, modest active research now. PE-22-28 sits at the thinnest end: a single research lineage, no independent replication, primary literature concentrated in two or three papers. Researchers planning experimental work should calibrate to this gradient rather than treat all eight compounds as comparable on evidence-base depth — and the Cerebrolysin compound guide covers the deepest-evidence end of this distribution in compound-level detail.

Per-compound regulatory framing

Regulatory status varies sharply across the eight compounds. Cerebrolysin is approved as a pharmaceutical primarily in Austria and parts of Eastern Europe, the Russian Federation, and several Asian markets; the research-grade material sold for in-vitro use is not interchangeable with the approved pharmaceutical product. Selank and Semax are approved as medications in the Russian Federation under nootropic and anxiolytic indications respectively, and are classified as research chemicals in all other jurisdictions. Dihexa, DSIP, Humanin, PE-22-28, and Pinealon are not approved by the FDA, EMA, or any regulatory agency in any major jurisdiction for human therapeutic use; in all jurisdictions they are research chemicals only. The Apex Laboratory editorial standards, documented at the Apex editorial standards page, treat per-compound regulatory framing as a non-negotiable accuracy boundary; certificates of analysis and batch verification for each compound are archived at the lab-verified archive.

Peptides versus synthetic small-molecule nootropics

Researchers comparing the nootropic peptides to synthetic small-molecule nootropics — racetams (piracetam, aniracetam, oxiracetam), ampakines, modafinil-class wakefulness compounds — encounter four genuine differences:

• Molecular size — peptides 350–2,700 Da versus small molecules typically under 500 Da
• Target specificity — peptides typically engage one or a few receptors at near-physiological concentrations; small molecules show broader off-target profiles
• BBB-transport mechanism — saturable receptor-mediated transcytosis or designed BBB-penetrant analogs versus passive diffusion across lipid bilayers
• Evidence-base maturity — the racetam family has decades of human clinical trial work but indistinct mechanism; several nootropic peptides have well-characterized mechanism but thin or geographically-isolated clinical literatures

The mechanism specificity of peptide compounds is the substantive point of difference. The evidence-base differences cut in the other direction.

Frequently Asked Questions

What are nootropic peptides?

Nootropic peptides are short chains of amino acids studied in published research for their effects on cognitive, neuroprotective, and CNS-signaling pathways. The category groups compounds by CNS-targeting research intent rather than by a shared receptor — Apex’s eight catalog compounds map across seven distinct mechanism families spanning neurotrophic-factor mimicry, GABAergic modulation, ion-channel inhibition, and mitochondrial signaling.

How do nootropic peptides work?

The category covers seven mechanism families: neurotrophic-factor-mimicking (Cerebrolysin, Dihexa); melanocortin and BDNF modulators (Semax); tuftsin-derived GABAergic anxiolytics (Selank); sleep-related neuropeptides (DSIP); ion-channel-targeted neurogenesis compounds (PE-22-28); mitochondrial-derived cytoprotectives (Humanin); and Khavinson bioregulators (Pinealon). Each engages a different receptor or pathway, so “how they work” is family-specific.

Which research peptides cross the blood-brain barrier?

Peptide BBB transport occurs through saturable receptor-mediated transcytosis, adsorptive transcytosis, and intranasal direct delivery — comprehensively reviewed in Banks (2015). Selank and Semax use intranasal routes in published research; Dihexa was engineered for BBB-penetration; Humanin is endogenously CNS-produced; Pinealon and PE-22-28 are short enough that simple permeation contributes alongside saturable carriers.

What is the difference between nootropic peptides and synthetic small-molecule nootropics like racetams?

The substantive differences are molecular size (peptides 350–2,700 Da versus small molecules under 500 Da), target specificity (peptides engage discrete receptors; racetams have indistinct mechanism), BBB-transport mechanism (saturable transport versus passive diffusion), and evidence base (peptides have characterized mechanism but thin clinical literature; racetams have decades of clinical work but contested mechanism).

Which CNS research peptides have the deepest published evidence base?

Cerebrolysin has the deepest published evidence — multiple randomized controlled trials (CARS, CASTA) plus a 2023 Cochrane systematic review. Selank and Semax have substantial Russian Academy of Sciences mechanism literature alongside Russian-language clinical trial publications. Humanin has substantive preclinical mechanism work. PE-22-28 has the thinnest evidence base, concentrated in a single research lineage.

Are any of these compounds approved medications?

Cerebrolysin is approved as a pharmaceutical primarily in Austria and parts of Eastern Europe, the Russian Federation, and several Asian markets. Selank and Semax are approved as medications in the Russian Federation only — research chemicals in all other jurisdictions. Dihexa, DSIP, Humanin, PE-22-28, and Pinealon are research chemicals globally and are not approved by the FDA, EMA, or any regulatory agency for human therapeutic use.

What is the Khavinson bioregulator concept?

The Khavinson bioregulator concept — developed at the Saint Petersburg Institute of Bioregulation and Gerontology and reviewed in Anisimov and Khavinson (2010) — proposes that short peptides interact with chromatin, DNA, and nucleosomes to modulate tissue-specific gene expression. Pinealon is the CNS-focused member; Epithalon is the most-studied member of the broader family.

Which of these compounds do researchers most often investigate sequentially?

Apex does not provide protocol guidance or stack recommendations. Across the published literature, researchers investigating CNS pathway questions most commonly begin with the deepest-evidence compound relevant to their hypothesis — Cerebrolysin for neurotrophic-factor mimicry, Selank or Semax for the Russian Academy of Sciences peptide program, Humanin for mitochondrial signaling — and treat each as an independent experimental subject rather than a stackable component.

Sourcing Research-Grade CNS Research Peptides

The validity of any CNS or nootropic peptides research depends directly on the purity and molecular authenticity of the compounds used. Degraded or impure material — whether from unverified vendors, improper storage, or lyophilized product that has been reconstituted before delivery — produces unreliable data regardless of how carefully the experimental design is constructed. At Apex Laboratory, every CNS research peptide is supplied as lyophilized material verified to ≥99% purity through dual HPLC and Mass Spectrometry analysis, with batch documentation archived at the lab-verified archive. The three most-researched compounds in the eight-compound catalog — covering three different mechanism families — are featured below; the full Nootropic Research Peptides category lists each of the eight catalog compounds with size and packaging details. Visit the About page for the quality-verification process.

Continue Your Research

Research Use Disclaimer

This article is provided for educational and research reference purposes only. The compounds discussed in this article and all products sold by Apex Laboratory are intended exclusively for in-vitro laboratory research use and are not for human consumption. Among the compounds covered, Cerebrolysin is approved as a pharmaceutical primarily in Austria and parts of Eastern Europe, the Russian Federation, and several Asian markets; Selank and Semax are approved as medications in the Russian Federation and classified as research chemicals in other jurisdictions; Dihexa, DSIP, Humanin, PE-22-28, and Pinealon are research chemicals globally. Researchers should consult the primary peer-reviewed literature cited throughout this article for detailed methodological protocols, experimental designs, and complete data sets.